DanHeart (H-HeFT / Met-HeFT) Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) Metformin in Patients with Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT) A randomized, 2 x 2 factorial designed, double-blind, placebo controlled study

Trial Profile

DanHeart (H-HeFT / Met-HeFT) Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) Metformin in Patients with Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT) A randomized, 2 x 2 factorial designed, double-blind, placebo controlled study

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Hydralazine/isosorbide dinitrate (Primary) ; Metformin (Primary)
  • Indications Chronic heart failure
  • Focus Adverse reactions
  • Acronyms DanHeart (H-HeFT / Met-HeFT); DanHeart (H-HeFT / Met-HeFT)
  • Most Recent Events

    • 17 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top